Camrelizumab Plus CAPOX Improves Survival in Gastric Cancer
Phase 3 trial shows camrelizumab plus CAPOX with maintenance therapy significantly improves overall survival vs CAPOX alone in HER2-negative gastric cancer.
Neuroscience Editor
Michael O'Connor is a neurologist and researcher at Tripler Army Medical Center in Honolulu. Board-certified in neurology and clinical neurophysiology, he covers brain research, neurological disorders, and psychiatric studies for Hawaii Medical Journal.
Phase 3 trial shows camrelizumab plus CAPOX with maintenance therapy significantly improves overall survival vs CAPOX alone in HER2-negative gastric cancer.